ProCE Banner Activity

CE / CME

Expert Insights on New Advances in the Treatment of Gastroenteropancreatic NETs

Text Module

Experts discuss advances in the diagnosis, management, and treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as well as their impact on patients’ quality of life. Improve your ability to optimally integrate the recommended diagnostic techniques and treatments based on current safety and efficacy data to better care for patients with GEP-NETs.

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: December 30, 2024

Expiration: December 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for medical, radiation, surgical oncologists, nurses, pharmacists and physician associates as well as other healthcare professionals treating patients with GEP-NETs.

Program Learning Goal

This activity aims to improve learners’ knowledge and competence to optimally integrate recommended diagnostic techniques and treatments into the management of patients with GEP-NETs.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Differentially diagnose GEP-NETs based on expert guidance regarding examinations, testing, and imaging

  • Apply current guidelines and recommendations to monitor for disease progression in patients with GEP-NETs

  • Select therapies and sequencing strategies for GEP-NETs based on current and emerging efficacy and safety evidence and patient- and disease-related factors

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Thor R. Halfdanarson, MD

Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, Minnesota

Thor R. Halfdanarson, MD: researcher: Advances Accelerator Applications (a Novartis Company), Camurus, Crinetics, Exelixis, ITM, Perspective Therapeutics, TerSera, Thermo Fisher Scientific; consultant/advisor/speaker: Camurus, ITM, Novartis.

Jonathan Strosberg, MD

Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, Florida

Jonathan Strosberg, MD: consultant/advisor/speaker: Boehringer Ingelheim, Exelixis.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Nicolle Rochino, PharmD, RPh and Kristi K. Orbaugh, MSN, RNP, AOCNP, as noted below.

Nicolle Rochino, PharmD, RPh: employee (relationship has ended): Novo Nordisk.

Kristi K. Orbaugh, MSN, RNP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Daichii Sankyo, Eli Lilly, Gilead, Pfizer, Regeneron, SOBI.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 30, 2024, through December 29, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-349-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until December 29, 2025. PAs should only claim credit commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.